Dr. Aurélien Marabelle is a research clinician with expertise in oncology (MD) and immunology (PhD). His clinical practice is dedicated to early phase Clinical trials in Cancer Immunotherapies. He works as a senior medical oncologist and an investigator within the Drug Development Department (DITEP) of Gustave Roussy.

Dr. Marabelle translational research focuses on mechanisms of action of immune checkpoint monoclonal antibodies and their adverse events (INSERM U1015 unit). He is also the director of the Clinical Investigation Center BIOTHERIS dedicated to intratumoral immunotherapies (INSERM CIC1428).

Dr. Marabelle obtained a MSc & PhD in Oncology & Immunology at Ecole Normale Supérieure de Lyon, King’s College London and University of Lyon. He attended medical school at the University of Paris VI and received his medical degree from the University of Clermont‐Ferrand. He completed his clinical fellowship in the pediatric hematology and oncology institute at the Léon Bérard Cancer Center in Lyon. He did his post-doctoral research training in Professor Ronald Levy´s lab at Stanford University, California, where he focused on strategies to overcome the resistance to immune checkpoint targeted therapies.

Dr. Marabelle is an active member of ESMO, ASCO, AACR, EATI and serves currently as President of the French Society of Cancer Immunotherapy (FITC).